Development of Small-Molecule Antivirals for Ebola

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F15%3A00450477" target="_blank" >RIV/61388963:_____/15:00450477 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1002/med.21355" target="_blank" >http://dx.doi.org/10.1002/med.21355</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/med.21355" target="_blank" >10.1002/med.21355</a>

Result language
angličtina
Original language name
Development of Small-Molecule Antivirals for Ebola
Original language description
Ebola hemorrhagic fever is a deadly disease caused by infection with one of the Ebola virus species. Although a significant progress has recently been made in understanding of Ebola virus biology and pathogenesis, development of effective anti-Ebola treatments has not been very productive, compared to other areas of antiviral research (e.g., HIV and HCV infections). No approved vaccine or medicine is available for Ebola but several are currently under development. This review summarises attempts in identification, evaluation, and development of small-molecule candidates for treatment of Ebola viral disease, including the most promising experimental drugs brincidofovir (CMX001), BCX4430, and favipiravir (T-705).
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
CC - Organic chemistry
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)